Literature DB >> 19484142

Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells.

Joseph Kwong1, Franky Leung Chan, Kwong-kwok Wong, Michael J Birrer, Kyra M Archibald, Frances R Balkwill, Ross S Berkowitz, Samuel C Mok.   

Abstract

In this study, we established an in vitro organoid model of normal human ovarian surface epithelial (HOSE) cells. The spheroids of these normal HOSE cells resembled epithelial inclusion cysts in human ovarian cortex, which are the cells of origin of ovarian epithelial tumor. Because there are strong correlations between chronic inflammation and the incidence of ovarian cancer, we used the organoid model to test whether protumor inflammatory cytokine tumor necrosis factor alpha would induce malignant phenotype in normal HOSE cells. Prolonged treatment of tumor necrosis factor alpha induced phenotypic changes of the HOSE spheroids, which exhibited the characteristics of precancerous lesions of ovarian epithelial tumors, including reinitiation of cell proliferation, structural disorganization, epithelial stratification, loss of epithelial polarity, degradation of basement membrane, cell invasion, and overexpression of ovarian cancer markers. The result of this study provides not only an evidence supporting the link between chronic inflammation and ovarian cancer formation but also a relevant and novel in vitro model for studying of early events of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484142      PMCID: PMC2685442          DOI: 10.1593/neo.09112

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  54 in total

Review 1.  Ovarian tumors. A review.

Authors:  R E Scully
Journal:  Am J Pathol       Date:  1977-06       Impact factor: 4.307

2.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

3.  Surface cells and inclusion cysts in fetal ovaries.

Authors:  A Blaustein
Journal:  Gynecol Oncol       Date:  1981-10       Impact factor: 5.482

4.  Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.

Authors:  Isabelle H Roland; Wan-Lin Yang; Dong-Hua Yang; Mary B Daly; Robert F Ozols; Thomas C Hamilton; Henry T Lynch; Andrew K Godwin; Xiang-Xi Xu
Journal:  Cancer       Date:  2003-12-15       Impact factor: 6.860

5.  Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk.

Authors:  Wan-Lin Yang; Andrew K Godwin; Xiang-Xi Xu
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

Review 6.  Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.

Authors:  Peter W Szlosarek; Frances R Balkwill
Journal:  Lancet Oncol       Date:  2003-09       Impact factor: 41.316

7.  An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors.

Authors:  Kate A Scott; Robert J Moore; Caroline H Arnott; Nick East; Richard G Thompson; Bernard J Scallon; David J Shealy; Frances R Balkwill
Journal:  Mol Cancer Ther       Date:  2003-05       Impact factor: 6.261

Review 8.  The cell of origin of ovarian epithelial tumours.

Authors:  Louis Dubeau
Journal:  Lancet Oncol       Date:  2008-12       Impact factor: 41.316

9.  Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids.

Authors:  Richard C Bates; Arthur M Mercurio
Journal:  Mol Biol Cell       Date:  2003-01-26       Impact factor: 4.138

10.  The pathogenesis of ovarian inclusion cysts and cystomas.

Authors:  S V Radisavljevic
Journal:  Obstet Gynecol       Date:  1977-04       Impact factor: 7.661

View more
  18 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 2.  Polyphenols and aging.

Authors:  Brannon L Queen; Trygve O Tollefsbol
Journal:  Curr Aging Sci       Date:  2010-02

3.  C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.

Authors:  Zhijian Gao; Xiaoyin Xu; Bruce McClane; Qing Zeng; Babak Litkouhi; William R Welch; Ross S Berkowitz; Samuel C Mok; Elizabeth I O Garner
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

4.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

5.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 6.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

7.  Diabetes-associated dysregulated cytokines and cancer.

Authors:  Yong Wu; Yanjun Liu; Yunzhou Dong; Jay Vadgama
Journal:  Integr Cancer Sci Ther       Date:  2016-02-15

Review 8.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

Review 9.  Opportunities for organoids as new models of aging.

Authors:  Jennifer L Hu; Michael E Todhunter; Mark A LaBarge; Zev J Gartner
Journal:  J Cell Biol       Date:  2017-12-20       Impact factor: 10.539

10.  Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours.

Authors:  Aleksandra Mielczarek-Palacz; Zdzisława Kondera-Anasz; Justyna Sikora
Journal:  Arch Med Sci       Date:  2012-10-30       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.